Over the past few years, immune checkpoint inhibitors (ICIs) targeting programmed cell death 1 (PD-1), its ligand 1 (PD-L1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) have radically changed the management of many types of solid tumors including melanoma [2]. This evidence concerns the gene CD274 and melanoma.